(Renal Cell Carcinoma) Is Keytruda Plus Inlyta Effective? KEYNOTE-426 5-Year Follow-Up Results

• July 5, 2023
• 1 min read

At ASCO 2023, held in Chicago from June 2–6, 2023, Brian I. Rini and colleagues from Vanderbilt-Ingram Cancer Center presented 5-year follow-up results from the KEYNOTE-426 Phase 3 clinical trial evaluating the efficacy and safety of pembrolizumab (Keytruda) plus axitinib (Inlyta) in treatment-naive renal cell carcinoma patients.

Trial Design:

The KEYNOTE-426 Phase 3 trial randomized treatment-naive renal cell carcinoma patients (N=861) 1:1 to:

• Pembrolizumab 200 mg + axitinib 5 mg twice daily (3-week cycle, N=432)
• Sunitinib (Sutent) 50 mg once daily

Primary endpoints were PFS and OS.

Results at median follow-up of 67.2 months:

Safety:

Treatment discontinuation rate: Keytruda + Inlyta 62.2% (237/381 patients) vs. Sutent 73.9% (300/406 patients). No new safety signals were identified.

Conclusion: Based on the KEYNOTE-426 5-year follow-up analysis, Brian I. Rini and colleagues concluded that Keytruda plus Inlyta demonstrated improved 5-year OS and PFS compared to Sutent monotherapy in treatment-naive renal cell carcinoma patients, supporting its continued use as a standard of care.

Source: https://meetings.asco.org/abstracts-presentations/219855

Renal Cell Carcinoma | Immunotherapy | Keytruda | Inlyta | KEYNOTE-426

• Clinical Trial Medications

• Immunotherapy

  • (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
  • (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
  • (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4